Lauren Elizabeth Heusinkveld, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratosis, Actinic | 4 | 2023 | 72 | 1.200 |
Why?
|
| Photochemotherapy | 4 | 2023 | 830 | 0.900 |
Why?
|
| Warts | 2 | 2019 | 66 | 0.790 |
Why?
|
| Deep Brain Stimulation | 6 | 2020 | 847 | 0.650 |
Why?
|
| Receptors, CXCR | 1 | 2018 | 52 | 0.590 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 457 | 0.510 |
Why?
|
| Parkinson Disease | 6 | 2020 | 2895 | 0.470 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2024 | 562 | 0.450 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 729 | 0.420 |
Why?
|
| Leukocytes | 1 | 2018 | 2030 | 0.340 |
Why?
|
| Aminolevulinic Acid | 3 | 2022 | 150 | 0.280 |
Why?
|
| Photosensitizing Agents | 4 | 2023 | 631 | 0.260 |
Why?
|
| Cell Movement | 1 | 2018 | 5215 | 0.250 |
Why?
|
| Antiparkinson Agents | 2 | 2016 | 184 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 3231 | 0.210 |
Why?
|
| Receptors, CCR1 | 1 | 2021 | 30 | 0.190 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 5857 | 0.170 |
Why?
|
| Tremor | 1 | 2018 | 195 | 0.140 |
Why?
|
| Cryptococcosis | 1 | 2016 | 103 | 0.130 |
Why?
|
| Cryptococcus neoformans | 1 | 2016 | 121 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 254 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 731 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 549 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1794 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2020 | 1585 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2742 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8562 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 2202 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2537 | 0.080 |
Why?
|
| Alleles | 1 | 2019 | 6892 | 0.070 |
Why?
|
| Pilot Projects | 5 | 2020 | 8731 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2016 | 2886 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2019 | 3078 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2018 | 12456 | 0.060 |
Why?
|
| Immunity | 2 | 2022 | 1003 | 0.060 |
Why?
|
| Patient Selection | 1 | 2018 | 4266 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 4069 | 0.060 |
Why?
|
| Aged | 8 | 2024 | 171562 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2024 | 81801 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 13020 | 0.060 |
Why?
|
| Philadelphia | 1 | 2023 | 271 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2022 | 65379 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 261 | 0.050 |
Why?
|
| Mice | 5 | 2022 | 82017 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 8051 | 0.050 |
Why?
|
| Humans | 13 | 2024 | 768393 | 0.050 |
Why?
|
| Male | 10 | 2024 | 364902 | 0.050 |
Why?
|
| Phenotype | 1 | 2019 | 16721 | 0.050 |
Why?
|
| Macrophages | 1 | 2016 | 5796 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13646 | 0.050 |
Why?
|
| Female | 10 | 2024 | 397089 | 0.040 |
Why?
|
| Scalp | 1 | 2023 | 391 | 0.040 |
Why?
|
| HIV-1 | 1 | 2018 | 6963 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 14784 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2021 | 286 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9493 | 0.040 |
Why?
|
| Rodentia | 1 | 2021 | 262 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 23631 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 660 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2021 | 652 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 18048 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2022 | 1655 | 0.040 |
Why?
|
| Animals | 5 | 2022 | 169337 | 0.030 |
Why?
|
| Middle Aged | 7 | 2024 | 223491 | 0.030 |
Why?
|
| Chemokines | 1 | 2021 | 962 | 0.030 |
Why?
|
| Eosinophils | 1 | 2021 | 953 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 3055 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 432 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 515 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 30228 | 0.030 |
Why?
|
| Ligands | 1 | 2021 | 3283 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 647 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1195 | 0.030 |
Why?
|
| Subthalamic Nucleus | 1 | 2016 | 203 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 18362 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3471 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2021 | 3663 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2024 | 41795 | 0.020 |
Why?
|
| Protein Binding | 1 | 2021 | 9343 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 2215 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5103 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14481 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 4357 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10863 | 0.010 |
Why?
|
| Prognosis | 1 | 2023 | 30022 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22355 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 13576 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39407 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 59686 | 0.010 |
Why?
|
| Risk Factors | 1 | 2023 | 74962 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 54920 | 0.010 |
Why?
|